State patients to benefit as Roche is persuaded to cut price of cancer …Business DayThe Department of Health has persuaded pharmaceutical company Roche to halve the price of its cancer drug rituximab, opening the way for the government to …and more…

Proactive Investors USA & CanadaSpectrum Pharmaceuticals Announces Outstanding ZEVALIN …EON: Enhanced Online News (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and … Deaths have occurred within 24 hours of ri…

Clinical Oncology NewsIn Follicular Lymphoma, Rituximab 'Retreatment' Better Than …Clinical Oncology NewsSan Diego—In previously untreated patients with low tumor burden (LTB) follicular lymphoma (FL), new Phase III data suggests that maint…

Proactive Investors USA & CanadaSpectrum Pharmaceuticals Announces Outstanding ZEVALIN …Business Wire (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) … Most (80%) fatalities occurred with …

Proactive Investors USA & CanadaSpectrum Pharmaceuticals Announces Outstanding ZEVALIN(R …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALI…

Proactive Investors USA & CanadaSpectrum Pharmaceuticals Announces Outstanding ZEVALIN(R) Clinical Data In …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN f…

Immunomedics reports initial clinical experience with epratuzumab …pharmabiz.com… unless they are combined with chemotherapy, such as rituximab + CHOP (R- … and rituximab + hyper-fractionated CVAD for mantle cell lymphoma (MCL).

Cell Therapeutics Appoints New Chief Medical OfficerManufacturing Digital (press release)The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial…

Cell Therapeutics Appoints New Chief Medical OfficerSacramento Bee… CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one …and more &ra…

Cell Therapeutics Appoints New Chief Medical OfficerBusiness Review India (press release)The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial…